Zepbound
Untracked preview. This is not a tracked Signal Bureau entity — the page is generated on request from live coverage search, is not indexed, and carries no editorial curation. Tracked entities live on the Wire.
If Zepbound is on your watch list: what changed in the coverage, what the reporting asserts, and what the crowd is pricing.
What’s changed
- Zepbound and Mounjaro may turn on the body’s calorie-burning brown fat · Latest Science News -- ScienceDaily · 2026-09-27
- FDA Flagged GLP-1 Vision Loss Signal in 2025, but U.S. Ozempic and Mounjaro Labels Still Lack NAION Warning · Medical Daily · 2026-09-29
- Eli Lilly Wavered Over the Last Month: One of Wall Street’s Biggest Banks Says 35% Gains Still to Come · 24/7 Wall St. · 2026-09-28
- Novo’s Next Blockbuster Is 71% the Drug It’s About to Lose · Business Model Analyst · 2026-09-26
- Novo CEO sees advantages in souping up NYSE listing: report · Fierce Pharma · 2026-09-24
- Eli Lilly CEO touts 70% share as Medicare GLP-1 program reaches 700K seniors · Fierce Pharma · 2026-09-24
What the reporting says
Across 24 tracked stories from 14 outlets, reporting on Zepbound most often describes public statements (2), acquisition (2), meetings or visits (2), price levels (1), regulatory approvals (1).
It shows up alongside GLP-1 (24), Eli Lilly (21), Mounjaro (19), Foundayo (9), FDA (11), Nyse (9).
Two steps out: AI (through GLP-1, 24 shared stories on the weaker link); Amgen (through Eli Lilly, 21 shared stories on the weaker link); Astrazeneca (through Eli Lilly, 21 shared stories on the weaker link); China (through GLP-1, 21 shared stories on the weaker link).
Tracked since Sep 3, with coverage on 15 separate days — concentrated in Auto and FDA Decisions.